Current research frameworks have devised classification or staging criteria for the characterization and diagnosis of AD according to amyloid, tau, and neurodegenerative biomarkers (A/T/N framework; (Jack Jr et al., 2018)). Here, MAPT is linked to Alzheimer disease.